OTC Decisions In February: 2 Switches, Label Changes For Excedrin, FeverAll, Naproxen From Biopharma
Executive Summary
FDA approved two switches on one day in February, diclofenac gel and olopatadine ophthalmic drops, and stayed busy on OTCs through the month with label changes for Excedrin Migraine packaged with 2-count pouches and for Taro's FeverAll suppositories, and an NDA approval for Biopharma's naproxen.
You may also be interested in...
OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies
Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.
Pataday Switch Approval Dilates Eye Drop Category As Alcon's OTC Sales Driver
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.
US OTC Switch Drought Ends: FDA Approves GSK Arthritis Gel, Alcon Allergy Eye Drops
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.